Cargando…
Cell-Free Methylated PTGER4 and SHOX2 Plasma DNA as a Biomarker for Therapy Monitoring and Prognosis in Advanced Stage NSCLC Patients
Notwithstanding some improvement in the earlier detection of patients with lung cancer, most of them still present with a late-stage disease at the time of diagnosis. Next to the most frequently utilized factors affecting the prognosis of lung cancer patients (stage, performance, and age), the recen...
Autores principales: | Fleischhacker, Michael, Arslan, Erkan, Reinicke, Dana, Eisenmann, Stefan, Theil, Gerit, Kollmeier, Jens, Schäper, Christoph, Grah, Christian, Klawonn, Frank, Holdenrieder, Stefan, Schmidt, Bernd |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
MDPI
2023
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10340633/ https://www.ncbi.nlm.nih.gov/pubmed/37443525 http://dx.doi.org/10.3390/diagnostics13132131 |
Ejemplares similares
-
Quantification of Cell-Free mSHOX2 Plasma DNA for Therapy Monitoring in Advanced Stage Non-Small Cell (NSCLC) and Small-Cell Lung Cancer (SCLC) Patients
por: Schmidt, Bernd, et al.
Publicado: (2015) -
Correlation of SHOX2 Gene Amplification and DNA Methylation in Lung Cancer Tumors
por: Schneider, Katja U, et al.
Publicado: (2011) -
Validation of the SHOX2/PTGER4 DNA Methylation Marker Panel for Plasma-Based Discrimination between Patients with Malignant and Nonmalignant Lung Disease
por: Weiss, Gunter, et al.
Publicado: (2017) -
Variants in the 5′UTR reduce SHOX expression and contribute to SHOX haploinsufficiency
por: Babu, Deepak, et al.
Publicado: (2020) -
SHOX2 DNA Methylation is a Biomarker for the diagnosis of lung cancer based on bronchial aspirates
por: Schmidt, Bernd, et al.
Publicado: (2010)